A study linked low testosterone to higher-grade biopsy progression during prostate cancer surveillance. Here is why it does not change care on its own.
On October 28, 2026, Medindia reported on a study by Lawen and colleagues published in The Journal of Urology that examined testosterone levels and later biopsy grade changes during prostate cancer active surveillance. The 2026 paper was titled “Low testosterone levels and grade group progression among localized prostate cancer patients on active surveillance.”
This article is for informational purposes only and is not medical advice. Decisions about prostate cancer follow-up or hormone treatment belong with a qualified clinician.
The study looked back at records from 924 men with localized prostate cancer enrolled in an active-surveillance program between 2005 and 2024. According to Medindia’s report, the researchers compared baseline testosterone with later changes in biopsy grade.
Baseline means the testosterone measurement used as the starting point for this analysis. The researchers classified results of 300 ng/dL or lower as low testosterone. This placed 272 men in the low-testosterone group, representing 29.4% of the cohort. The mean baseline testosterone for the whole cohort was 394 ng/dL.
The authors examined progression using separate biopsy-grade thresholds. For Grade Group 3 or higher, the low-testosterone group had a higher adjusted hazard of progression. For Grade Group 2 or higher, the association was not statistically significant.
The report used the term “extreme progression” for a biopsy showing Grade Group 3 or higher. That label describes the study’s chosen grade outcome. It does not by itself mean that cancer spread beyond the prostate.
The authors reported an adjusted hazard ratio of 1.61 for progression to Grade Group 3 or higher in the low-testosterone group. The 95% confidence interval was 1.02 to 2.54, with P=0.04.
A hazard ratio is a relative comparison between study groups. It is not the percentage of men who progressed and it does not give an individual man’s absolute risk. Reading the figure as a direct prediction for a personal test result would change the meaning of the finding.
For progression to Grade Group 2 or higher, the adjusted hazard ratio was 1.25. The 95% confidence interval was 0.93 to 1.67, with P=0.13. Medindia’s report describes this association as not statistically significant.
The two outcomes therefore need to remain separate. The statistically significant finding at the higher grade threshold should not become a claim that low testosterone predicts every form of progression. Equally, the lack of statistical significance at the other threshold does not erase the reported higher-grade association.
According to Medindia’s account, the study was observational and retrospective. It examined existing records rather than testing a strategy to change testosterone levels. It identifies an association but does not establish that low testosterone caused the later grade changes.
The study also did not show that raising testosterone prevents progression or that higher testosterone protects against aggressive disease. Whether a hormone level is associated with an outcome is a different question from whether hormone treatment changes that outcome.
The word “adjusted” does not resolve this distinction. A statistically adjusted association is still different from evidence that changing testosterone would change the cancer’s course.
The confidence interval for the Grade Group 3-or-higher finding was broad. Medindia’s report identifies this as uncertainty about the precise size of the association. The headline result is best understood alongside that interval rather than as a fixed effect that will repeat in every setting.
The cohort consisted of men with localized cancer receiving active surveillance. The result should not be assumed to apply to metastatic prostate cancer or to every treatment setting. Likewise, the proportion classified as having low testosterone describes this cohort rather than all men with prostate cancer.
The 300 ng/dL cutoff was a research definition for this analysis. A result at or below it is not proof of aggressive cancer. A single low result also does not establish testosterone deficiency.
The report says the study did not establish that testosterone testing improves risk prediction or outcomes beyond existing assessments. It calls for prospective studies in more diverse populations using contemporary surveillance methods before testosterone is considered a routine progression marker.
The unresolved clinical question is whether adding this measurement would improve assessment or care decisions. Finding an association is an initial step toward answering that question, not the completed answer.
The immediate clinical message is continuity rather than a new testing schedule. Medindia’s report advises men on active surveillance to continue their recommended follow-up. The study alone is not a reason to change PSA testing, imaging or biopsy timing.
For a man reviewing this news with his treating team, it helps to distinguish three questions:
Keeping those questions separate makes the conversation more precise. A biopsy finding and a hormone measurement were different parts of this study. The clinical discussion should not turn them into interchangeable measures of a person’s cancer status.
For related background, Testostra’s guide explains PSA in the wider prostate assessment. The aim is to understand the parts of the assessment rather than let one hormone headline take over the follow-up plan.
A separate question is whether symptoms warrant evaluation for testosterone deficiency. A 2026 review in Nature Reviews Urology describes diagnosis as requiring symptoms plus biochemical confirmation. It says testing typically involves morning testosterone measurements.
The review also notes that free testosterone and SHBG can help clarify borderline results or findings that do not agree. Their role is to support interpretation within the broader hormone assessment. The European Association of Urology’s guidance likewise places testosterone-deficiency evaluation in clinical context.
Men researching possible explanations for low-testosterone symptoms can bring both the symptom question and the laboratory question to a qualified clinician. Testostra’s overview of the context around testosterone testing provides related educational background.
This approach keeps a cancer-related research finding from replacing a symptom assessment. Concerns about possible testosterone deficiency can receive appropriate attention while the prostate cancer team continues its own evaluation and follow-up.
The European Association of Urology’s male-hypogonadism guidance says safety data for testosterone therapy are unclear in men on active surveillance or treated with non-surgical curative intent. Its treatment recommendations emphasize counselling about insufficient long-term safety data in prostate-cancer settings.
For men with prostate cancer considering testosterone therapy, the appropriate setting is an individualized discussion with a qualified clinician. That conversation should distinguish evaluation of possible testosterone deficiency from the decision about treatment. A research cutoff should not become a personal prescription.
The distinction is especially important here because the study’s question concerned baseline hormone levels and subsequent biopsy findings. The treatment discussion belongs with the clinician who can consider the person’s cancer setting alongside the hormone assessment and current guidance.
Bottom line: This finding deserves further research rather than an immediate change in medical practice. Clinician-directed surveillance remains the basis for follow-up. The study does not introduce a new surveillance standard or establish a change in testosterone-treatment guidance.
A cancer-progression finding may raise concern about low testosterone without supplying a treatment answer. Testostra puts such findings alongside clear explanations of symptoms and hormone testing, helping men distinguish questions worth discussing with a clinician from claims that go beyond the evidence.
Testostra follows testosterone research, clinical guidance and emerging evidence without turning general information into personal treatment advice.
Send us a question, research idea or topic suggestion. Reader questions help shape future Testostra content.
Contact Testostra